CRISPR Therapeutics

Company Overview

CRISPR Therapeutics is a prominent gene editing company that develops CRISPR/Cas9-based therapies. The company uses CRISPR to disrupt, delete, correct, and insert genes to treat genetic diseases and engineer advanced cellular therapies. Its therapeutic portfolio spans four core franchises. In hemoglobinopathies, their lead program, CASGEVY, is approved for severe sickle cell disease and transfusion-dependent beta-thalassemia, with ongoing research in stem cell editing. In immuno-oncology and autoimmune disorders, they are advancing gene-edited CAR T cell therapies. The company also targets common and rare diseases through in vivo approaches, starting with cardiovascular disease. Additionally, they are developing stem cell therapies for type 1 diabetes that eliminate the need for chronic immunosuppression.

The company has established strategic partnerships with industry leaders like Bayer and Vertex Pharmaceuticals. It has a strong presence in Switzerland and the U.S., with its U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations in Boston, Massachusetts, and San Francisco, California, as well as business offices in London, U.K.

Financial Highlights (FY 2024)

Company's Business Segments

• Gene Editing : CRISPR therapeutics